File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Comparative Immunogenicity of Several Enhanced Influenza Vaccine Options for Older Adults: A Randomized, Controlled Trial

TitleComparative Immunogenicity of Several Enhanced Influenza Vaccine Options for Older Adults: A Randomized, Controlled Trial
Authors
Keywordsinfluenza
vaccination
public health
Issue Date2019
PublisherOxford University Press. The Journal's web site is located at http://www.oxfordjournals.org/our_journals/cid/
Citation
Clinical Infectious Diseases, 2019, Epub 2019-12-12 How to Cite?
AbstractBackground: Enhanced influenza vaccines may improve protection for older adults, but comparative immunogenicity data are limited. Our objective was to examine immune responses to enhanced influenza vaccines, compared to standard-dose vaccines, in community-dwelling older adults. Methods: Community-dwelling older adults aged 65–82 years in Hong Kong were randomly allocated (October 2017–January 2018) to receive 2017–2018 Northern hemisphere formulations of a standard-dose quadrivalent vaccine, MF59-adjuvanted trivalent vaccine, high-dose trivalent vaccine, or recombinant-hemagglutinin (rHA) quadrivalent vaccine. Sera collected from 200 recipients of each vaccine before and at 30-days postvaccination were assessed for antibodies to egg-propagated vaccine strains by hemagglutination inhibition (HAI) and to cell-propagated A/Hong Kong/4801/2014(H3N2) virus by microneutralization (MN). Influenza-specific CD4+ and CD8+ T cell responses were assessed in 20 participants per group. Results: Mean fold rises (MFR) in HAI titers to egg-propagated A(H1N1) and A(H3N2) and the MFR in MN to cell-propagated A(H3N2) were statistically significantly higher in the enhanced vaccine groups, compared to the standard-dose vaccine. The MFR in MN to cell-propagated A(H3N2) was highest among rHA recipients (4.7), followed by high-dose (3.4) and MF59-adjuvanted (2.9) recipients, compared to standard-dose recipients (2.3). Similarly, the ratio of postvaccination MN titers among rHA recipients to cell-propagated A(H3N2) recipients was 2.57-fold higher than the standard-dose vaccine, which was statistically higher than the high-dose (1.33-fold) and MF59-adjuvanted (1.43-fold) recipient ratios. Enhanced vaccines also resulted in the boosting of T-cell responses. Conclusions: In this head-to-head comparison, older adults receiving enhanced vaccines showed improved humoral and cell-mediated immune responses, compared to standard-dose vaccine recipients. Clinical Trials Registration: NCT03330132.
DescriptionLink to Free access
Persistent Identifierhttp://hdl.handle.net/10722/281981
ISSN
2019 Impact Factor: 8.313
2015 SCImago Journal Rankings: 4.742

 

DC FieldValueLanguage
dc.contributor.authorCowling, BJ-
dc.contributor.authorPerera, RAPM-
dc.contributor.authorValenburg, SA-
dc.contributor.authorLeung, NHL-
dc.contributor.authorIuliano, AD-
dc.contributor.authorTam, YH-
dc.contributor.authorWong, JHF-
dc.contributor.authorFang, VJ-
dc.contributor.authorLi, APY-
dc.contributor.authorSo, HC-
dc.contributor.authorIp, DKM-
dc.contributor.authorAzziz-Baumgartner, E-
dc.contributor.authorFry, AM-
dc.contributor.authorLevine, MZ-
dc.contributor.authorGangappa, S-
dc.contributor.authorSambhara, S-
dc.contributor.authorBarr, IG-
dc.contributor.authorSkowronski, DM-
dc.contributor.authorPeiris, JSM-
dc.contributor.authorThompson, MG-
dc.date.accessioned2020-04-19T03:33:42Z-
dc.date.available2020-04-19T03:33:42Z-
dc.date.issued2019-
dc.identifier.citationClinical Infectious Diseases, 2019, Epub 2019-12-12-
dc.identifier.issn1058-4838-
dc.identifier.urihttp://hdl.handle.net/10722/281981-
dc.descriptionLink to Free access-
dc.description.abstractBackground: Enhanced influenza vaccines may improve protection for older adults, but comparative immunogenicity data are limited. Our objective was to examine immune responses to enhanced influenza vaccines, compared to standard-dose vaccines, in community-dwelling older adults. Methods: Community-dwelling older adults aged 65–82 years in Hong Kong were randomly allocated (October 2017–January 2018) to receive 2017–2018 Northern hemisphere formulations of a standard-dose quadrivalent vaccine, MF59-adjuvanted trivalent vaccine, high-dose trivalent vaccine, or recombinant-hemagglutinin (rHA) quadrivalent vaccine. Sera collected from 200 recipients of each vaccine before and at 30-days postvaccination were assessed for antibodies to egg-propagated vaccine strains by hemagglutination inhibition (HAI) and to cell-propagated A/Hong Kong/4801/2014(H3N2) virus by microneutralization (MN). Influenza-specific CD4+ and CD8+ T cell responses were assessed in 20 participants per group. Results: Mean fold rises (MFR) in HAI titers to egg-propagated A(H1N1) and A(H3N2) and the MFR in MN to cell-propagated A(H3N2) were statistically significantly higher in the enhanced vaccine groups, compared to the standard-dose vaccine. The MFR in MN to cell-propagated A(H3N2) was highest among rHA recipients (4.7), followed by high-dose (3.4) and MF59-adjuvanted (2.9) recipients, compared to standard-dose recipients (2.3). Similarly, the ratio of postvaccination MN titers among rHA recipients to cell-propagated A(H3N2) recipients was 2.57-fold higher than the standard-dose vaccine, which was statistically higher than the high-dose (1.33-fold) and MF59-adjuvanted (1.43-fold) recipient ratios. Enhanced vaccines also resulted in the boosting of T-cell responses. Conclusions: In this head-to-head comparison, older adults receiving enhanced vaccines showed improved humoral and cell-mediated immune responses, compared to standard-dose vaccine recipients. Clinical Trials Registration: NCT03330132.-
dc.languageeng-
dc.publisherOxford University Press. The Journal's web site is located at http://www.oxfordjournals.org/our_journals/cid/-
dc.relation.ispartofClinical Infectious Diseases-
dc.rightsPre-print: Journal Title] ©: [year] [owner as specified on the article] Published by Oxford University Press [on behalf of xxxxxx]. All rights reserved. Pre-print (Once an article is published, preprint notice should be amended to): This is an electronic version of an article published in [include the complete citation information for the final version of the Article as published in the print edition of the Journal.] Post-print: This is a pre-copy-editing, author-produced PDF of an article accepted for publication in [insert journal title] following peer review. The definitive publisher-authenticated version [insert complete citation information here] is available online at: xxxxxxx [insert URL that the author will receive upon publication here].-
dc.subjectinfluenza-
dc.subjectvaccination-
dc.subjectpublic health-
dc.titleComparative Immunogenicity of Several Enhanced Influenza Vaccine Options for Older Adults: A Randomized, Controlled Trial-
dc.typeArticle-
dc.identifier.emailCowling, BJ: bcowling@hku.hk-
dc.identifier.emailPerera, RAPM: mahenp@hku.hk-
dc.identifier.emailValenburg, SA: sophiev@hku.hk-
dc.identifier.emailLeung, NHL: nanleung@connect.hku.hk-
dc.identifier.emailTam, YH: yhtam@hku.hk-
dc.identifier.emailSo, HC: haso9150@hku.hk-
dc.identifier.emailIp, DKM: dkmip@hku.hk-
dc.identifier.emailPeiris, JSM: malik@hkucc.hku.hk-
dc.identifier.authorityCowling, BJ=rp01326-
dc.identifier.authorityPerera, RAPM=rp02500-
dc.identifier.authorityValenburg, SA=rp02141-
dc.identifier.authorityLeung, NHL=rp02637-
dc.identifier.authorityTam, YH=rp01881-
dc.identifier.authorityIp, DKM=rp00256-
dc.identifier.authorityPeiris, JSM=rp00410-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1093/cid/ciz1034-
dc.identifier.scopuseid_2-s2.0-85094684536-
dc.identifier.hkuros309701-
dc.identifier.volumeEpub 2019-12-12-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats